| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0,0 € | -100.0% | 223,8 k € | -42.9% | 392,0 k € | -68.8% | 1,3 M € | +209.5% | 406,1 k € | — | — | — | — | — | — | — | — | ||||||||||
| Gross margin | — | — | — | — | — | 244,5 k € | -44.3% | 438,9 k € | +135.8% | 186,2 k € | +269.2% | 50,4 k € | -55.7% | 113,8 k € | +133.0% | -345,3 k € | -227.6% | 270,6 k € | +6.0% | 255,3 k € | -2.0% | 260,6 k € | ||||||
| EBITDA | 581,2 k € | -43.6% | 1,0 M € | +14.3% | 902,5 k € | +31.8% | 684,9 k € | -49.0% | 1,3 M € | +367.5% | -501,9 k € | -61.3% | -311,3 k € | -201.0% | -103,4 k € | -933.7% | 12,4 k € | -85.0% | 82,9 k € | +120.2% | -410,4 k € | -304.5% | 200,7 k € | -13.5% | 232,1 k € | -7.8% | 251,7 k € | |
| Operating profit | 382,9 k € | -42.7% | 668,2 k € | +13.6% | 588,1 k € | +314.4% | 141,9 k € | -78.6% | 662,4 k € | +151.0% | -1,3 M € | +51.7% | -2,7 M € | -232.2% | -808,5 k € | -133.4% | -346,4 k € | -288.8% | -89,1 k € | +81.3% | -477,4 k € | -348.8% | 191,9 k € | -14.2% | 223,8 k € | -8.1% | 243,4 k € | |
| Profit/loss | 486,7 k € | -35.3% | 752,1 k € | +15.8% | 649,4 k € | +366.0% | 139,4 k € | -78.8% | 656,3 k € | +151.6% | -1,3 M € | +51.7% | -2,6 M € | -225.0% | -811,3 k € | -133.6% | -347,3 k € | -265.8% | -95,0 k € | +80.4% | -484,6 k € | -366.6% | 181,7 k € | -9.7% | 201,2 k € | +24.8% | 161,3 k € | |
| Equity | 5,6 M € | +9.6% | 5,1 M € | +17.4% | 4,3 M € | +17.7% | 3,7 M € | +3.9% | 3,5 M € | +22.8% | 2,9 M € | +80.7% | 1,6 M € | -35.7% | 2,5 M € | +213.1% | 792,3 k € | -30.5% | 1,1 M € | +529.5% | -265,4 k € | -221.0% | 219,2 k € | +484.9% | 37,5 k € | +3.3% | 36,3 k € | |
| Total assets | 6,5 M € | +10.4% | 5,9 M € | +9.7% | 5,4 M € | +3.4% | 5,2 M € | +24.1% | 4,2 M € | -21.9% | 5,4 M € | +128.9% | 2,3 M € | -18.4% | 2,9 M € | +110.1% | 1,4 M € | +7.2% | 1,3 M € | +276.2% | 339,0 k € | +10.7% | 306,3 k € | +7.0% | 286,4 k € | +5.0% | 272,7 k € | |
| Cash | — | — | — | — | — | 387,0 k € | -52.0% | 806,5 k € | +9.7% | 735,3 k € | +799.0% | 81,8 k € | -32.4% | 120,9 k € | +145.1% | 49,4 k € | -77.8% | 222,5 k € | +15.8% | 192,2 k € | +1.7% | 189,0 k € | ||||||
| Debts | 941,3 k € | +15.5% | 815,0 k € | -22.2% | 1,0 M € | -31.2% | 1,5 M € | +140.5% | 632,9 k € | -74.5% | 2,5 M € | +240.7% | 728,1 k € | +86.8% | 389,8 k € | -32.1% | 574,4 k € | +345.4% | 128,9 k € | -78.6% | 601,8 k € | +591.2% | 87,1 k € | -65.0% | 248,9 k € | +5.3% | 236,5 k € | |
| Staff | 17,9 | 16,8 | 16,9 | 14,8 | 12,6 | 11,8 | 9 | 5 | 3,7 | 1,4 | 1 | 1 | 0,3 | — | ||||||||||||||
Public limited company · Evergem · incorporated on 17/01/2012 · 17,9 ETP
Public limited company profitable and well capitalised. Cash position declining (-52.0%).
Solid counterparty for a standard engagement.
Boehringer Ingelheim Veterinary Medicine Belgium NV is a Public limited company incorporated in 2012. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Evergem. It employs on average 17,9 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette